Drugs / Selatogrel
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07615868 | Jun → Oct 2026 expected | coronary artery disorder | Viatris Innovation GmbH | Recruiting | No outcome recorded |
| Phase 1 | NCT07133191 | Oct → Nov 2025 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04557280 | Nov → Dec 2020 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04406896 | Jul → Oct 2020 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03814200 | Jan → Feb 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03593278 | Jul → Aug 2018 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03430661 | Jan 2018 → May 2019 | — | Viatris Innovation GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01954615 | Oct 2011 → Mar 2012 | — | Idorsia Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT03487445 | Jul → Nov 2018 | acute myocardial infarction | Viatris Innovation GmbH | Completed | Mixed |
| Phase 2 | NCT03384966 | Jan → Aug 2018 | coronary atherosclerosis | Viatris Innovation GmbH | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04957719 | Aug 2021 → Dec 2026 expected | acute myocardial infarction | Viatris Innovation GmbH | Enrolling by invitation | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-09-03 | Idorsia Pharmaceuticals Ltd. | Results Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019 idorsia.com ↗
Idorsia Ltd (SIX: IDIA) today announced that the positive results of two Phase 2 clinical studies with selatogrel, a highly-selective P2Y12 receptor antagonist, were presented at the European Society of Cardiology 2019 Congress in Paris, France. |
| 2018-12-18 | Idorsia Pharmaceuticals Ltd. | Results Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective idorsia.com ↗
The predefined extent of platelet aggregation inhibition was seen in at least 89% of the patients in both chronic and acute situations across doses. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-26 | Idorsia Pharmaceuticals Ltd. | Idorsia and Viatris update their collaboration for selatogrel and cenerimod idorsia.com ↗ |
| 2021-06-28 | Idorsia Pharmaceuticals Ltd. | Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction idorsia.com ↗ |
| 2019-11-19 | Idorsia Pharmaceuticals Ltd. | Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel idorsia.com ↗ |
| 2019-09-03 | Idorsia Pharmaceuticals Ltd. | Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019 idorsia.com ↗ |
| 2018-12-18 | Idorsia Pharmaceuticals Ltd. | Idorsia's P2Y12 receptor antagonist - selatogrel - Phase 2 clinical studies meet their objective idorsia.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Selatogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04957719 ↗ |
| Known as | ACT-246475 | “Randomized Trial to Assess the Pharmacokinetics, the Pharmacodynamics, and the Tolerability of a Single 16 mg Dose of Selatogrel (ACT-246475) in Chinese Adults With Chronic...” NCT07615868 ↗6“Single s.c. dose of 16 mg ACT-246475 including 3.7 MBq (100 μCi) 14C-radiolabeled ACT 246475” NCT03593278 ↗ “pharmacokinetics of selatogrel (ACT-246475).” NCT04406896 ↗ |
| Action | Inhibit | “Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration.” NCT03384966 ↗1“Purinergic receptor P2Y12 antagonist” CHEMBL4297589 ↗ |
| Modality | Small molecule | — CHEMBL4297589 ↗ |
| Route | Oral | “single, oral dose of ACT-246475” NCT01954615 ↗ |
| Target | P2RY12 | “Purinergic receptor P2Y12 antagonist” CHEMBL4297589 ↗ |